Tag: Medtronic

Medtronic Announces First Patient Treated in TERMINATE AF Clinical Trial

DUBLIN – December 3, 2018 – Medtronic plc (NYSE:MDT) today announced the first patient treated in the TERMINATE AF trial, a multi-center study evaluating two surgical ablation devices – the Cardioblate(TM) Irrigated RF (IRF) System and the CryoFlex(TM) Surgical Ablation System – for the treatment of non-paroxysmal (persistent or longstanding persistent) […]

Edwards Lifesciences and Medtronic Lead the U.S. TAVR Market, Despite Threat of New Competition – New Analysis from iData Research

VANCOUVER, British Columbia–(BUSINESS WIRE)–According to a new series of reports by iData Research, the United States cardiac surgery device market is valued at $5.7 billion USD and is forecast to exceed $10 billion by 2024. The largest segment of the cardiac surgery market is the transcatheter heart valve replacement (THVR) […]

New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System

DUBLIN and NEW YORK – November 16, 2018 – Medtronic plc (NYSE:MDT) today announced new data on the Heli-FX(TM) EndoAnchor(TM) system, which demonstrated durability, safety and efficacy in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those with hostile aortic neck anatomies. The new data were unveiled in presentations at the […]

Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System

DUBLIN – November 13, 2018 – Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt traumatic aortic injuries (BTAI), penetrating atherosclerotic ulcers (PAU), […]

MEDTRONIC TO ANNOUNCE FINANCIAL RESULTS FOR ITS SECOND QUARTER OF FISCAL YEAR 2019

DUBLIN – November 9, 2018 – Medtronic plc (NYSE:MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news […]

MEDTRONIC BEGINS RENAL DENERVATION STUDY FOR HIGH BLOOD PRESSURE PATIENTS PRESCRIBED ANTI-HYPERTENSIVE MEDICATION

DUBLIN – November 8, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications. The SPYRAL HTN-ON MED Trial is the […]

Medtronic Presents IN.PACT SFA Trial Five-Year Data and Total IN.PACT All-Subjects Analysis in VIVA Late Breaking Clinical Trials

(GLOBE NEWSWIRE via COMTEX) –New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS – November 6, 2018 – Medtronic plc (NYSE:MDT) data presented today reinforce the durability, safety, and effectiveness of the IN.PACT(TM) Admiral(TM) drug-coated balloon […]

Medtronic Receives FDA Approval for Valiant Navion(TM) Thoracic Stent Graft System

DUBLIN – October 23, 2018 – Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), blunt thoracic aortic […]